Identification
- Summary
Gadodiamide is a gadolinium-based contrast agent used for the visualization of lesions with vascularity during magnetic resonance imaging (MRI) scans.
- Brand Names
- Omniscan
- Generic Name
- Gadodiamide
- DrugBank Accession Number
- DB00225
- Background
Gadodiamide is a paramagnetic gadolinium-based contrast agent (GBCA) that is used in MR imaging procedures to assist in the visualization of blood vessels. It is intravenously injected and is commonly marketed under the trade name Omniscan.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Gadodiamide (DB00225)
- Weight
- Average: 573.66
Monoisotopic: 574.10225 - Chemical Formula
- C16H26GdN5O8
- Synonyms
- Gadodiamida
- Gadodiamide
- Gadodiamide anhydrous
- External IDs
- S-041
Pharmacology
- Indication
For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, gadodiamide shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, gadodiamide primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadodiamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadodiamide in lesions such as neoplasms, abscesses, and subacute infarcts.
- Absorption
Not Available
- Volume of distribution
- 200 ± 61 mL/kg
- Protein binding
Not Available
- Metabolism
There is no detectable biotransformation or decomposition of gadodiamide.
- Route of elimination
Gadodiamide is eliminated primarily in the urine.
- Half-life
Two-compartment model with mean distribution and elimination half-lives (reported as mean ± SD) of 3.7 ± 2.7 minutes and 77.8 ± 16 minutes, respectively.
- Clearance
- Renal cl=1.7 mL/min/kg
- Plasma cl=1.8 mL/min/kg
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Gadodiamide may decrease the excretion rate of Abacavir which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Gadodiamide which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Gadodiamide which could result in a higher serum level. Acetaminophen Gadodiamide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Gadodiamide which could result in a higher serum level. Aclidinium Gadodiamide may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Gadodiamide may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Gadodiamide which could result in a higher serum level. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Gadodiamide which could result in a higher serum level. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Gadodiamide hydrate 0RPE15QPL0 122795-43-1 WYKPQCVMUQQKCL-UHFFFAOYSA-K - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Omniscan Injection 287 mg/1mL Intravenous GE Healthcare Inc. 2006-09-21 Not applicable US 
Omniscan Solution 287 mg / mL Intravenous Ge Healthcare 1997-03-25 Not applicable Canada 
Omniscan Injection 287 mg/1mL Intravenous GE Healthcare Inc. 2002-04-19 Not applicable US Omniscan Liq IV 287mg/ml Liquid 287 mg / mL Intravenous Sanofi 1994-12-31 1997-07-30 Canada
Categories
- ATC Codes
- V08CA03 — Gadodiamide
- Drug Categories
- Acetates
- Acids, Acyclic
- Amines
- Compounds used in a research, industrial, or household setting
- Contrast Media
- Coordination Complexes
- Diagnostic Uses of Chemicals
- Drugs that are Mainly Renally Excreted
- Injections, Intravenous
- Magnetic Resonance Contrast Activity
- Magnetic Resonance Imaging Contrast Media
- Miscellaneous Therapeutic Agents
- Other Diagnostics
- Paramagnetic Contrast Agent
- Paramagnetic Contrast Media
- Polyamines
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- Alpha amino acids / Tricarboxylic acids and derivatives / Trialkylamines / Secondary carboxylic acid amides / Carboxylic acid salts / Amino acids / Carboxylic acids / Organopnictogen compounds / Organic zwitterions / Organic salts show 3 more
- Substituents
- Aliphatic acyclic compound / Alpha-amino acid / Alpha-amino acid amide / Amine / Amino acid / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative show 12 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- gadolinium coordination entity (CHEBI:37333)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 84F6U3J2R6
- CAS number
- 131410-48-5
- InChI Key
- HZHFFEYYPYZMNU-UHFFFAOYSA-K
- InChI
- InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3
- IUPAC Name
- gadolinium(3+) 2-[bis({2-[(carboxylatomethyl)[(methylcarbamoyl)methyl]amino]ethyl})amino]acetate
- SMILES
- [Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 24847884
- PubChem Substance
- 46504789
- ChemSpider
- 135661
- 41144
- ChEBI
- 37333
- PharmGKB
- PA164784027
- RxList
- RxList Drug Page
- Wikipedia
- Gadodiamide
- MSDS
- Download (56.3 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Not Available Chronic Kidney Disease (CKD) / Impaired Renal Function 1 4 Recruiting Other Cognitive Functioning / Contrast Medium / Motor Function 1 4 Recruiting Supportive Care Nephrogenic Fibrosing Dermopathy 1 3 Completed Diagnostic Anatomic renal artery stenosis 1 3 Completed Diagnostic Aorto-Iliac Stenosis / Arterial Occlusive Diseases 1
Pharmacoeconomics
- Manufacturers
- Ge healthcare
- Packagers
- Amersham Health Inc.
- GE Healthcare Inc.
- Dosage Forms
Form Route Strength Injection, solution Intravenous 287 mg/ml Injection Intravenous Injection Intravenous 287 mg/1mL Injection, solution Intravenous Solution Intravenous 287 mg / mL Solution Intravenous 287 mg/1ml Injection Intravenous 0.5 mmol/ml Injection, solution Intravenous 0.5 mmol/ml Liquid Intravenous 287 mg / mL Solution Intravenous 287 mg Solution Intravenous - Prices
Unit description Cost Unit Omniscan prefill plus syringe 7.02USD ml Omniscan 287 mg/ml vial 6.98USD ml Omniscan 287 mg/ml bottle 6.49USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5560903 No 1996-10-01 2013-10-01 US US5362475 No 1994-11-08 2011-11-08 US CA1335819 No 1995-06-06 2012-06-06 Canada
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 5.21 mg/mL ALOGPS logP 0.02 ALOGPS logP -8.7 Chemaxon logS -2.1 ALOGPS pKa (Strongest Acidic) 1.02 Chemaxon pKa (Strongest Basic) 8.34 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 11 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 188.31 Å2 Chemaxon Rotatable Bond Count 16 Chemaxon Refractivity 132.4 m3·mol-1 Chemaxon Polarizability 40.47 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.9808 Blood Brain Barrier + 0.62 Caco-2 permeable - 0.5605 P-glycoprotein substrate Substrate 0.7041 P-glycoprotein inhibitor I Non-inhibitor 0.9016 P-glycoprotein inhibitor II Non-inhibitor 0.9571 Renal organic cation transporter Non-inhibitor 0.9031 CYP450 2C9 substrate Non-substrate 0.8265 CYP450 2D6 substrate Non-substrate 0.8189 CYP450 3A4 substrate Non-substrate 0.5872 CYP450 1A2 substrate Non-inhibitor 0.9416 CYP450 2C9 inhibitor Non-inhibitor 0.9189 CYP450 2D6 inhibitor Non-inhibitor 0.9566 CYP450 2C19 inhibitor Non-inhibitor 0.8972 CYP450 3A4 inhibitor Non-inhibitor 0.9864 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9927 Ames test Non AMES toxic 0.8343 Carcinogenicity Non-carcinogens 0.8563 Biodegradation Not ready biodegradable 0.7604 Rat acute toxicity 1.9159 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9582 hERG inhibition (predictor II) Non-inhibitor 0.9424
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Drug created at June 13, 2005 13:24 / Updated at February 05, 2023 22:13